WillItSurvive
Pharma and healthcare groups · United States

Intellia Therapeutics

intelliatx.com ↗

Biotech using CRISPR gene editing to build one-time cures, starting with hereditary angioedema.

Losing its protection
Assessed 24 July 2026 · Evidence as of 24 July 2026
The structural protection is eroding.
On the recordSince 24 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: Nex-z Phase 3 re-enrollment (MAGNITUDE trials) after the clinical hold
The call

Intellia's one-shot CRISPR cure looks real on paper, but it still has to clear FDA review and a safety scare before it can compete with drugs already in patients' hands.

Intellia uses CRISPR technology to edit genes inside patients' bodies to treat rare diseases. The company is hard to replace because it has years of scientific work, patent protection, and already published results that competitors would need to match from scratch. No other company is close behind, and AI cannot speed up the slow process of proving these treatments are safe in real patients. The one thing that matters most: whether the FDA approves Intellia's lead drug (lonvo-z) by mid-2027, and whether another drug (nex-z) can restart testing after a patient death caused the FDA to pause it.

Why
01
AI pressure: None apparent. AI tools speed up target discovery industry-wide but don't touch the FDA approval process Intellia's survival depends on. Could AI do the core job? Unlikely.
02
Bigger players: Takeda's Takhzyro (lanadelumab) and BioCryst's Orladeyo. Doctors already prescribe these approved HAE prophylactics, giving them years of use before lonvo-z can reach patients. Could a giant copy it? No, they are blocked.
03
What protects it. A positive Phase 3 result plus NEJM publication and a rolling BLA give Intellia a regulatory head start rivals can't copy fast.
What would change this call
FDA approval decision on lonvo-z BLA, targeted H1 2027. Approval would convert Intellia's clinical lead into a shipped, revenue-generating product.
Nex-z Phase 3 (MAGNITUDE/MAGNITUDE-2) re-enrollment in H2 2026 without new safety events. Clean restart would show the clinical hold was isolated, not a platform-wide safety flaw.
Any additional equity or debt raise announced before commercial launch. Terms and size would show how much dilution or financial strain remains before lonvo-z revenue arrives.
Key numbers
  • 87% cut in HAE attacks vs placebo in Phase 3 (2026-04-27)
  • $517M cash on hand, runway into H2 2027 (2026-05-11)
  • $180M raised at $10.75/share, April 2026 (2026-04-29)
Named risks
  • FDA rejects or delays lonvo-z BLA past H1 2027 target launch. Severity: high
  • New nex-z safety signal triggers another clinical hold after October 2025 death. Severity: high
  • Additional dilutive capital raise needed before commercial launch given ~$80M/quarter burn. Severity: medium
  • Repeated workforce reductions (2024, 2025) signal ongoing financial strain. Severity: medium
  • ATTR market already has entrenched commercial competitors Intellia must displace post-launch. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
CRISPR Therapeutics / Vertexlosing toCasgevy already commercial for sickle cell/beta-thalassemia; Intellia has no approved product as of mid-2026
Alnylamlosing toAmvuttra already commercial in ATTR market that Intellia's nex-z targets, as of 2026
BridgeBiolosing toAttruby already commercial in ATTR indications while nex-z remains in Phase 3 post clinical hold, 2026
Beam TherapeuticscontestingCompeting base-editing platform vying for gene-editing capital and pipeline leadership through 2026
Prime Medicinegaining onSmaller prime-editing peer also pursuing in vivo gene correction approaches as of 2026
Questions people ask
Is Intellia Therapeutics profitable in 2026?
No. Intellia has no approved products and reported trailing twelve month net loss of about $413 million as of 2026-07-17, against TTM revenue of only $66 to 68 million from collaboration deals like Regeneron, per MarketBeat data.
Could AI replace Intellia Therapeutics' drug development work?
Unlikely. AI/ML is used industry-wide for guide-RNA design and off-target prediction, but Intellia's value rests on clinical trial data, FDA regulatory relationships, and manufacturing, none of which AI can substitute, per a 2024-12-20 review of gene-editing AI use.
Who is Intellia Therapeutics' biggest competitor?
CRISPR Therapeutics, partnered with Vertex Pharmaceuticals, already markets Casgevy, the first approved CRISPR therapy, for sickle cell disease and beta-thalassemia, while Intellia still has zero approved products as of mid-2026.
Who owns Intellia Therapeutics?
Intellia is an independent public company trading on Nasdaq as NTLA since its May 2016 IPO that raised $102 million, with no controlling corporate parent; John Leonard, M.D. serves as CEO as of April 2026.
Did Intellia Therapeutics have layoffs?
Yes. Intellia announced a 15% workforce reduction in January 2024, then a further roughly 27% net reduction on 2025-01-09, discontinuing its NTLA-3001 alpha-1 antitrypsin program and incurring about $8 million in restructuring charges.
What happened with Intellia's nex-z safety issue?
Both nex-z Phase 3 trials were placed on FDA clinical hold on 2025-10-29 after a patient death involving Grade 4 liver transaminase and bilirubin elevation; the holds were lifted in January 2026 (MAGNITUDE-2) and March 2026 (MAGNITUDE) with added liver monitoring.
Timeline
  • 2026-07-23Market cap approximately $1.55 to 1.6 billion, stock near $11.30 per share
  • 2026-06-13Additional HAELO Phase 3 lonvo-z results published in New England Journal of Medicine
  • 2026-05-11Q1 2026 results show cash of $517 million, collaboration revenue $15.0 million
  • 2026-04-29Priced $180 million public offering at $10.75 per share, upsized from $150 million
  • 2026-04-27Reported first-ever positive Phase 3 for in vivo CRISPR therapy, lonvo-z in HAE
  • 2026-03-02FDA lifted clinical hold on MAGNITUDE Phase 3 trial for nex-z in ATTR cardiomyopathy
  • 2026-01-26FDA lifted clinical hold on MAGNITUDE-2, enrollment target raised to about 60 patients
  • 2025-11-06Q3 2025 update detailed nex-z clinical hold and safety investigation status
  • 2025-10-29Both nex-z Phase 3 trials placed on FDA clinical hold after a patient death
  • 2025-01-09Announced approximately 27% workforce reduction and discontinued NTLA-3001 program
Revision history
24 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Community Health SystemsViatrisAccendra Health
More in Pharma and healthcare groups →
Sources